2,3,5-Substituted tetrahydrofurans as cancer chemopreventives. Part 1: Synthesis and anti-cancer activities of 5-hydroxymethyl-2,3-diaryl-tetrahydro-furan-3-ols

Bioorganic and Medicinal Chemistry

Volumn 15, Issue 12, 2007, Pages 3990-3996

  Singh, Palwinder ^a   Mittal, Anu ^a   Kumar, Subodh ^a  

^a GURU NANAK DEV UNIVERSITY   (India)

Author keywords

2,3 Diaryltetrahydrofurans; 59 Human tumor cell lines; Allylation; Anti cancer agents; Benzoins; Cancer propagation; COX 2; Epoxidation

Indexed keywords

2,3 BIS(4 CHLOROPHENYL) 5 HYDROXYMETHYLTETRAHYDROFURAN 3 OL; 3 CHLOROPERBENZOIC ACID; FURAN DERIVATIVE; UNCLASSIFIED DRUG;

ALLYLATION; ANALYTIC METHOD; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYCLIZATION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LEUKEMIA;

ANTICARCINOGENIC AGENTS; CELL DIVISION; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FURANS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; SPECTROMETRY, MASS, FAST ATOM BOMBARDMENT;

EID: 34247585524     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2007.04.004     Document Type: Article

References (23)

1. Meric J.-B., Rottey S., Olaussen K., Soria J.-C., Khayat D., Rixe O., and Spano J.-P. Critical Rev. Oncol. Hemat 59 (2006) 51 references therein
2. Subbaramaiah K., and Dannenberg A.J. Trends in Pharmacol. Sci 24 (2003) 96
3. Brown J.R., and DuBois R.N. J. Clin. Oncol. 23 (2005) 2840
4. Hull M.A. Eur. J. Cancer 41 (2005) 1854
5. Pereg D., and Lishner M. J. Int. Med. 258 (2005) 115
6. Chow L.W.C., Loo W.T.Y., and Toi M. Biomed. Pharmacotherapy 59 (2005) S281
7. Mann J.R., and DuBois R.N. Cancer J. 10 (2004) 145
8. Ricchi P., Zarrilli R., Palma A.d., and Acquaviva A.M. Br. J. Cancer 88 (2003) 803
9. Peek Jr. R.M. Cancer Chemother. Pharmacol. 54 (2004) S50
10. Raz A. Biochem. Pharmacol. 63 (2002) 343
11. Marnett L.J., and DuBois R.N. Annu. Rev. Pharmacol. Toxicol. 42 (2002) 55
12. Baron J.A., and Sandler R.S. Annu. Rev. Med. 51 (2000) 511
13. Asako H., Kubes P., Wallace J., Gaginella T., Wolf R.E., and Granger D.N. Am. J. Physiol. 262 (1992) G903
14. Gilroy D.W., Tomlinson A., and Willoughby D.A. Eur. J. Pharmacol. 355 (1998) 211
15. Pommery N., Taverne T., Telliez A., Goossens L., Charlier C., Pommery J., Goossens J.-F., Houssin R., Durant F., and Henichart J.-P. J. Med. Chem. 47 (2004) 6195
16. Singh P., Mittal A., Kaur S., and Kumar S. Bioorg. Med. Chem. 14 (2006) 7910 COX-2 inhibitory activities of present compounds will be reported separately
17. Kumar S., Kaur P., Mittal A., and Singh P. Tetrahedron 62 (2006) 4018
18. Kumar S., Kaur P., Chimni S.S., and Singh P. Synlett 9 (2001) 1431
19. Ally M.C., Scudiero D.A., Monks P.A., Hursy M.L., Czerwinski M.J., Fine D.A., Abbott B.J., Mayo J.G., Showmaker R.H., and Boyd M.R. Cancer Res. 48 (1988) 589
20. Grever M.R., Schepartz S.A., and Chabner B.A. Semin. Oncol. 19 (1992) 622
21. Boyd M.R., and Paull K.D. Drug Dev. Res. 34 (1995) 91
22. NCI database (www.dtp.nci.nih.gov), NSC 19893.
23. Hodgson H.H., and Rosenberg W. J. Chem. Soc. (1930) 14